Aquestive Therapeutics, Inc. AQST Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $44.55M-22.6% | $57.56M+13.8% | $50.58M+6.1% | $47.68M-6.2% | ||
| $18.56M+3.8% | $17.87M-14.2% | $20.83M+7.5% | $19.39M— | ||
| $25.99M-34.5% | $39.69M+33.4% | $29.75M+5.2% | $28.29M— | ||
| 58.3%-10.6pp | 69%+10.1pp | 58.8%-0.5pp | 59.3%— | ||
| $17.19M-15.2% | $20.28M+54.8% | $13.1M-25.0% | $17.48M+2.5% | ||
| $79.85M+59.1% | $50.18M+58.0% | $31.75M-40.0% | $52.88M-1.1% | ||
| $115.6M+30.9% | $88.33M+34.5% | $65.69M-26.8% | $89.75M— | ||
| -$71.05M-131% | -$30.77M-104% | -$15.1M+64.1% | -$42.07M-21.3% | ||
| -159.5%-106pp | -53.5%-23.6pp | -29.9%+58.4pp | -88.2%-20.0pp | ||
| $11.12M0.0% | $11.12M+75.5% | $6.34M-3.3% | $6.55M-34.8% | ||
| -$83.78M-89.8% | -$44.15M-479% | -$7.63M+86.0% | -$54.41M+22.9% | ||
| -$83.78M-89.8% | -$44.14M-461% | -$7.87M+85.5% | -$54.41M+22.9% | ||
| -188.1%-111pp | -76.7%-61.1pp | -15.6%+98.6pp | -114.1%+24.7pp | ||
| -$0.79-51.9% | -$0.52-247% | -$0.15+86.7% | -$1.13+38.6% | ||
| -$0.79-51.9% | -$0.52-373% | -$0.11+90.3% | -$1.13+38.6% | ||
| 412.3M+20.4% | 342.3M+33.2% | 257.1M+36.0% | 189.1M+26.1% | ||
| 412.3M+20.4% | 342.3M+43.3% | 238.9M+26.4% | 189.1M+26.1% | ||
| $5.74M+5.1% | $5.46M+503% | $905K— | $0— | ||
| $4.37M+27.1% | $3.44M-78.9% | $16.32M+16,386% | $99K— | ||
| $243K+3.0% | $236K+7.3% | $220K-96.3% | $5.89M-52.5% | ||
| -$83.78M-89.8% | -$44.14M-461% | -$7.87M+85.5% | -$54.41M+22.9% | ||
| $44.55M-22.6% | $57.56M+13.8% | $50.58M+6.1% | $47.68M-6.2% | ||
| -$71.05M-131% | -$30.77M-104% | -$15.1M+64.1% | -$42.07M-21.3% | ||
| -$70.5M-135% | -$30.05M-118% | -$13.76M+65.3% | -$39.68M-25.1% | ||
| -$70.5M-135% | -$30.05M-118% | -$13.76M+65.3% | -$39.68M-25.1% | ||
| -158.3%-106pp | -52.2%-25.0pp | -27.2%+56.0pp | -83.2%-20.8pp | ||
| -$71.05M-131% | -$30.77M-104% | -$15.1M+64.1% | -$42.07M-21.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Aquestive Therapeutics, Inc.'s revenue?
- Aquestive Therapeutics, Inc. (AQST) generated $50.3M in revenue over the trailing twelve months, down 7.3% year over year.
- Is Aquestive Therapeutics, Inc. profitable?
- Aquestive Therapeutics, Inc. is not currently profitable: it reported a net loss of $68.9M over the trailing twelve months, a -137.1% net margin.
- What are Aquestive Therapeutics, Inc.'s profit margins?
- Gross margin is 63.5% and operating margin is -111.2%, with a -137.1% net margin.
- What is Aquestive Therapeutics, Inc.'s earnings per share?
- Aquestive Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-0.62.
- Where does Aquestive Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Aquestive Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
